Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 2 records in total 2
    records per page

    Novel surrogate virus neutralization test reveals low serum SERO neutralizing anti-SARS-CoV-2-S antibodies SERO levels in mildly affected COVID-19 convalescents

    Authors: Berislav Bošnjak; Saskia Catherina Stein; Stefanie Willenzon; Anne Katrin Cordes; Wolfram Puppe; Günter Bernhardt; Inga Ravens; Christiane Ritter; Christian R Schultze-Florey; Nina Gödecke; Jörg Martens; Hannah Kleine-Weber; Markus Hoffmann; Anne Cossmann; Mustafa Yilmaz; Isabelle Pink; Marius M Hoeper; Georg MN Behrens; Stefan Pöhlmann; Rainer Blasczyk; Thomas F Schulz; Reinhold Förster

    doi:10.1101/2020.07.12.20151407 Date: 2020-07-14 Source: medRxiv

    Neutralizing antibodies SERO targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) block severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) entry into cells using surface-expressed angiotensin-converting enzyme 2 (ACE2). We developed a surrogate neutralization test (sVNT) to assess at what degree serum SERO antibodies SERO interfere with the binding of SARS-CoV-2-S-RBD MESHD to ACE2. The sVNT revealed neutralizing anti-SARS-CoV-2-S antibodies SERO in the sera of 90% of mildly and 100% of severely affected coronavirus-disease-2019 (COVID-19) convalescent patients. Importantly, sVNT results correlated strongly to the results from pseudotyped- vesicular stomatitis MESHD stomatitis HP virus-vector-based neutralization assay and to levels of anti-SARS-CoV-2-S1 IgG and IgA antibodies SERO. Moreover, levels of neutralizing antibodies SERO also correlated to duration and severity of clinical symptoms, but not patient age TRANS or gender TRANS. These findings together with the sVNT will not only be important for evaluating the prevalence SERO of neutralizing antibodies SERO in a population but also for identifying promising plasma SERO donors for successful passive antibody SERO therapy.

    Evaluation of Neutralizing Antibodies SERO against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies SERO Using Vesicular Stomatitis Virus MESHD Stomatitis HP Virus ( Vsv MESHD) Pseudovirus-Based Assay

    Authors: Sarah A. Almahboub; Abdullah Algaissi; Mohamed A. Alfaleh; M-Zaki ElAssouli; Anwar M. Hashem

    id:10.20944/preprints202005.0379.v1 Date: 2020-05-23 Source:

    Emerging highly pathogenic human coronaviruses (CoVs) represent a serious ongoing threat to the public health worldwide. The spike (S) proteins of CoVs are surface glycoproteins that facilitate viral entry into host cells via attachment to their respective cellular receptors. The S protein is believed to be a major immunogenic component of CoVs and a target for neutralizing antibodies SERO (nAbs) and most candidate vaccines. Development of a safe and convenient assay is thus urgently needed to determine the prevalence SERO of CoVs nAbs in the population, to study immune response in infected individuals, and to aid in vaccines and viral entry inhibitors evaluation. While live virus-based neutralization assays are used as gold standard serological methods to detect and measure nAbs, handling of highly pathogenic live CoVs requires strict bio-containment conditions in biosafety level-3 laboratories. On the other hand, use of replication-incompetent pseudoviruses bearing CoVs S proteins could represent a safe and useful method to detect nAbs in serum samples SERO under biosafety level-2 conditions. Here, we describe a detailed protocol of a safe and convenient assay to generate vesicular stomatitis virus MESHD stomatitis HP virus ( VSV MESHD)-based pseudoviruses to evaluate and measure nAbs against highly pathogenic CoVs. The protocol covers methods to produce VSV MESHD pseudovirus bearing the S protein of the Middle East respiratory syndrome-CoV (MERS-CoV) MESHD and the severe acute respiratory syndrome-CoV-2 MESHD (SARS-CoV-2), pseudovirus titration, and pseudovirus neutralizing assay. Such assay could be adapted by different laboratories and researchers working on highly pathogenic CoVs without the need to handle live viruses in biosafety level-3 environment.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.